Literature DB >> 10029061

Arsenic targets tubulins to induce apoptosis in myeloid leukemia cells.

Y M Li1, J D Broome.   

Abstract

Arsenic exhibits a differential toxicity to cancer cells. At a high concentration (>5 microM), As2O3 causes acute necrosis in various cell lines. At a lower concentration (0.5-5 microm), it induces myeloid cell maturation and an arrest in metaphase, leading to apoptosis. As2O3-treated cells have features found with both tubulin-assembling enhancers (Taxol) and inhibitors (colchicine). Prior treatment of monomeric tubulin with As2O3 markedly inhibits GTP-induced polymerization and microtubule formation in vitro but does not destabilize GTP-induced tubulin polymers. Cross-inhibition experiments indicate that As2O3 is a noncompetitive inhibitor of GTP binding to tubulin. These observations correlate with the three-dimensional structure of beta-tubulin and suggest that the cross-linking of two vicinal cysteine residues (Cys-12 and Cys-213) by trivalent arsenic inactivates the GTP binding site. Furthermore, exogenous GTP can prevent As2O3-induced mitotic arrest.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10029061

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  27 in total

1.  Trivalent arsenic inhibits the functions of chaperonin complex.

Authors:  Xuewen Pan; Stefanie Reissman; Nick R Douglas; Zhiwei Huang; Daniel S Yuan; Xiaoling Wang; J Michael McCaffery; Judith Frydman; Jef D Boeke
Journal:  Genetics       Date:  2010-07-26       Impact factor: 4.562

2.  Oxidation and methylation status determine the effects of arsenic on the mitotic apparatus.

Authors:  A D Kligerman; C L Doerr; A H Tennant
Journal:  Mol Cell Biochem       Date:  2005-11       Impact factor: 3.396

3.  Arsenic Trioxide as a Vascular Disrupting Agent: Synergistic Effect with Irinotecan on Tumor Growth Delay in a CT26 Allograft Model.

Authors:  Jong Cheol Lee; Ho Yong Lee; Chang Hoon Moon; Seung Ju Lee; Won Hyeok Lee; Hee Jeong Cha; Sungchan Park; Young Han Lee; Hyun Jin Park; Ho-Taek Song; Young Joo Min
Journal:  Transl Oncol       Date:  2013-02-01       Impact factor: 4.243

Review 4.  From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia.

Authors:  Sai-Juan Chen; Guang-Biao Zhou; Xiao-Wei Zhang; Jian-Hua Mao; Hugues de Thé; Zhu Chen
Journal:  Blood       Date:  2011-03-21       Impact factor: 22.113

5.  Basic mechanisms of arsenic trioxide (ATO)-induced apoptosis in human leukemia (HL-60) cells.

Authors:  Clement Yedjou; Paul Tchounwou; John Jenkins; Robert McMurray
Journal:  J Hematol Oncol       Date:  2010-08-26       Impact factor: 17.388

6.  Anticancer effect of realgar nanoparticles on mouse melanoma skin cancer in vivo via transdermal drug delivery.

Authors:  Qi-Hong Zhao; Ying Zhang; Yun Liu; Hui-Li Wang; Yuan-Yuan Shen; Wen-Jun Yang; Long-Ping Wen
Journal:  Med Oncol       Date:  2009-03-12       Impact factor: 3.064

7.  Identification of arsenic-binding proteins in human breast cancer cells.

Authors:  Xinyan Zhang; Fan Yang; Joong-Youn Shim; Kenneth L Kirk; D Eric Anderson; Xiaoxin Chen
Journal:  Cancer Lett       Date:  2007-05-17       Impact factor: 8.679

8.  Arsenic trioxide suppresses paclitaxel-induced mitotic arrest.

Authors:  Q Duan; E Komissarova; W Dai
Journal:  Cell Prolif       Date:  2009-04-24       Impact factor: 6.831

9.  Comparative functional genomic analysis identifies distinct and overlapping sets of genes required for resistance to monomethylarsonous acid (MMAIII) and arsenite (AsIII) in yeast.

Authors:  William J Jo; Alex Loguinov; Henri Wintz; Michelle Chang; Allan H Smith; Dave Kalman; Luoping Zhang; Martyn T Smith; Chris D Vulpe
Journal:  Toxicol Sci       Date:  2009-07-27       Impact factor: 4.849

10.  Arsenite-induced mitotic death involves stress response and is independent of tubulin polymerization.

Authors:  B Frazier Taylor; Samuel C McNeely; Heather L Miller; J Christopher States
Journal:  Toxicol Appl Pharmacol       Date:  2008-03-14       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.